EGFR Mutations, ROS1, and ALK Rearrangements in Iranian Non-Small Cell Lung Cancer Patients

نویسندگان
Mabani, Maryam ID 1
Rostami, Parsa ID 2
Madadkar Borna, Marziye ID 3
Jamali, Elaheh Sadat ID 4
Shiari, Sarah ID 5
Salimi, Babak ID 6
Seifi, Sharareh ID 7
Dehghanifard, Ali ID 8
Khosravi, Negin ID 9
Sattari, Hanieh ID 10
Khosravi, Adnan ID 11

1 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Department of Biology, East Tehran Islamic azad university,Tehran, Iran.

4 Immunology Department, Pasteur Institue of Iran, Tehran, Iran.

5 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

6 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

7 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

8 Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

9 Department of Genetic, Ahar Branch, Islamic Azad University, Ahar, Iran.

10 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

11 Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

doi
10.61186/ijbc.17.1.40
چکیده

Background: Driver mutations, particularly in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1 genes, are prevalent in non-small cell lung cancer (NSCLC) and significantly influence patient outcomes. These mutations have become crucial biomarkers for targeted therapy, guiding treatment decisions and improving patient survival. Our study aims ...

کلیدواژه‌ها
ALK, ROS1, EGFR, Non-small cell lung carcinoma